Research programme: CNS disorders therapeutics - LundbeckAlternative Names: LSP1-2111; Lu AF21934
Latest Information Update: 03 Oct 2014
At a glance
- Originator Lundbeck A/S
- Class Antibodies; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 4 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
- 08 Feb 2011 Early research is ongoing in Denmark